Geranylgeraniol - A new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw

Oral Oncology

Volumn 47, Issue 3, 2011, Pages 195-201

  Ziebart, T ^a   Koch, F ^a   Klein, M O ^a   Guth, J ^a   Adler, J ^a   Pabst, A ^a   Al Nawas, B ^a   Walter, C ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Bisphosphonate associated osteonecrosis of the jaws; Geranylgeraniol; Prevention; Therapy; Wound healing

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GERANYLGERANIOL; IBANDRONIC ACID; MEVALONIC ACID; PAMIDRONIC ACID; PHALLACIDIN; ZOLEDRONIC ACID;

ARTICLE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; JAW OSTEONECROSIS; OSTEOBLAST; PRIORITY JOURNAL; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DITERPENES; ENDOTHELIAL CELLS; FIBROBLASTS; HUMANS; JAW DISEASES; OSTEOBLASTS; OSTEONECROSIS;

EID: 79952281111     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.12.003     Document Type: Article

References (36)

1. A.A. Khan, G.K. Sándor, E. Dore, A.D. Morrison, M. Alsahli, and F. Amin Bisphosphonate associated osteonecrosis of the jaw J Rheumatol 36 3 2009 478 490
2. B.J. Edwards, J.W. Hellstein, P.L. Jacobsen, S. Kaltman, A. Mariotti, and C.A. Migliorati Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs Am Dent Assoc 139 12 2008 1674 1677
3. S.W. Rabkin, and P. Sunga The effect of doxorubicin (adriamycin) on cytoplasmic microtubule system in cardiac cells J Mol Cell Cardiol 19 1987 1073 1083 (Pubitemid 18029096)
4. F. Saad Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid Semin Oncol 29 2002 19 (6 Suppl 21)
5. S.D. Reed, J.I. Radeva, G.A. Glendenning, F. Saad, and K.A. Schulman Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer J Urol 171 2004 1537
6. D.C. Crick, D.A. Andres, and C.J. Waechter Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation Biochem Biophys Res Commun 237 1997 483 487 (Pubitemid 27434709)
7. J.E. Fisher, M.J. Rogers, J.M. Halasy, S.P. Luckman, D.E. Hughes, and P.J. Masarachia Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proc Natl Acad Sci USA 96 1999 133 138 (Pubitemid 29036065)
8. E. van Beek, C. Lowik, G. Van der Pluijm, and S. Papapoulos The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates J Bone Miner Res 14 1999 722 729 (Pubitemid 29210598)
9. C.M. Shipman, P.I. Croucher, R.G.G. Russell, M.H. Helfrich, and M.J. Rogers The bisphosphonate incardinate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway Cancer Res 58 1998 5294 5297 (Pubitemid 28551102)
10. J.P. Coxon, G.M. Oades, R.S. Kirby, and K.W. Colston Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation BJU Int 94 2004 164 170 (Pubitemid 38980328)
11. S.S. Virtanen, H.K. Vaananen, P.L. Harkonen, and P.T. Lakkakorpi Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 62 2002 2708 2714 (Pubitemid 34462756)
12. K. Iguchi, T. Nakano, S. Usui, and K. Hirano Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells Cancer Lett 237 2 2006 223 233 Epub 2005 Jul 12 (Pubitemid 43777074)
13. G.M. Oades, S.G. Senaratne, I.A. Clarke, R.S. Kirby, and K.W. Colston Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells J Urol 170 1 2003 246 252 (Pubitemid 36734471)
14. S.S. Virtanen, H.K. Vaananen, P.L. Harkonen, and P.T. Lakkakorpi Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 62 9 2002 2708 2714 (Pubitemid 34462756)
15. K. Walker, and M.F. Olson Targeting Ras and Rho GTPases as opportunities for cancer therapeutics Curr Opin Genet Dev 15 1 2005 Feb 62 68 (Pubitemid 40127633)
16. T. Ziebart, A. Pabst, M.O. Klein, P. Kammerer, L. Gauss, and D. Brüllmann Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro Clin Oral Investig 2009
17. A. Allegra, A. Alonci, G. Penna, A. Granata, E. Nastro Siniscalchi, and G. Oteri Bisphosphonates Induce Apoptosis of Circulating Endothelial Cells in Multiple Myeloma Patients and in Subjects with Bisphosphonate-Induced Osteonecrosis of the Jaws Acta Haematol 124 2 2010 79 85
18. M.H. Abu-Id, P.H. Warnke, J. Gottschalk, I. Springer, J. Wiltfang, and Y. Acil Bis-phossy jaws - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw J Craniomaxillofac Surg 36 2008 95 103
19. K. Hashimoto, K.I. Morishige, K. Sawada, M. Tahara, S. Shimizu, and S. Ogata Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells Biochem Biophys Res Comm 354 2007 478 484 (Pubitemid 46161348)
20. I.R. Reid, M.J. Bolland, and A.B. Grey Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41 2007 318 320 (Pubitemid 47199147)
21. V.D.P. Correia, C.L. Caldeira, and M.M. Marques Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament broblasts Dent Traumatol 22 2006 312 317 (Pubitemid 44683659)
22. M.S. Moreira, E. Katayama, A.C. Bombana, and M.M. Marques Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. A pilot study. Dent Traumatol 21 2005 329 335 (Pubitemid 41687773)
23. A.J. Roelofs, K. Thompson, S. Gordon, and M.J. Rogers Molecular mechanisms of action of bisphosphonates: current status Clin Cancer Res 12 2006 6222S 6230S (Pubitemid 44703794)
24. C. Walter, M.O. Klein, A. Pabst, B. Al-Nawas, H. Duschner, and T. Ziebart Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells Clin Oral Investig 14 1 2010 35 41 Epub 2009 Mar 18
25. K.A. Groetz, and B. Al-Nawas Persisting alveolar sockets-a radiologic symptom of BP-ONJ? J Oral Maxillofac Surg 64 10 2006 1571 1572 (Pubitemid 44374173)
26. T. Van den Wyngaert, T. Claeys, M.T. Huizing, J.B. Vermorken, and E. Fossion Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome Ann Oncol 20 2 2009 Feb 331 336
27. R.A. Williamson Surgical management of bisphosphonate induced osteonecrosis of the jaws Int J Oral Maxillofac Surg 39 3 2010 251 255
28. Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis 2010. [Epub ahead of print].
29. S.L. Ruggiero, and B. Mehrotra Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management Annu Rev Med 60 2009 85 96
30. P. Vescovi, M. Manfredi, E. Merigo, M. Meleti, C. Fornaini, and J.P. Rocca Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT) Lasers Med Sci 25 1 2010 101 113
31. J.J. Freiberger, R. Padilla-Burgos, A.H. Chhoeu, K.H. Kraft, O. Boneta, and R.E. Moon Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series J Oral Maxillofac Surg 65 7 2007 1321 1327 (Pubitemid 46907400)
32. J.J. Freiberger Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 67 5 Suppl. 2009 96 106
33. H.L. Benford, J.C. Frith, S. Auriola, J. Mönkkönen, and M.J. Rogers Farnesol and Geranylgeraniol prevent activation of caspase by aminobisphopsphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drug Mol Pharmacol 56 1999 131 140 (Pubitemid 29309821)
34. Koch FP, Merkel C, Al-Nawas B, Smeets R, Ziebart T, Walter C, Wagner W. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner - A quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg 2010. [Epub ahead of print].
35. S. Otto, C. Pautke, C. Opelz, I. Westphal, I. Drosse, and J. Schwager Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism J Oral Maxillofac Surg 68 11 2010 2837 2845
36. C. Denoyelle, L. Hong, J.-P. Vannier, J. Soria, and C. Soria New insights into the action of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and-independent effects Br J Cancer 88 10 2003 1631 1640 (Pubitemid 36713793)